Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2019-02-21FDA Approved: DIAZEPAM — Supplemental Application (Hospira, Inc.)
The FDA approved a supplemental application for diazepam from Hospira, Inc., indicating updated labeling and continued availability under th…
-
FDA approval · 2019-02-19FDA Approved: ETHOSUXIMIDE — Original Application (Strides Pharma Science Limited)
FDA approves Strides Pharma Science Limited's original ANDA for ethosuximide, a generic treatment for absence seizures in epilepsy.
-
CLINICAL_TRIALS research · 2019-02-05Clinical Trial Update: Trial for Epilepsy Patients Non-responsive to AEDs Using Medical App
This document provides an update on a clinical trial evaluating a medical app for epilepsy patients who are non-responsive to anti-epileptic…
-
FDA approval · 2019-01-30FDA Approved: CLOBAZAM — Original Application (Micro Labs Limited)
The FDA approved Micro Labs Limited's generic CLOBAZAM (clobazam) under Original Application ANDA211711.
-
CLINICAL_TRIALS trial_result · 2019-01-22Clinical Trial Update: Treatment of Drug Resistant Epilepsy
A ClinicalTrials.gov update shows that the study on treatment of drug-resistant epilepsy sponsored by the University of Florida is no longer…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-01-15Clinical Trial Update: Modified Atkins Diet in Childhood Epilepsy [Phase 2, Phase 3]
Clinical trial update on the Modified Atkins Diet for refractory childhood epilepsy, showing Phase 2 and Phase 3 data.
-
CLINICAL_TRIALS trial_result · 2019-01-15Clinical Trial Update: Efficacy of a Simplified Modified Atkins Diet in Children With Refractory Epilepsy [Phase 2, Phase 3]
Clinical trial update on the efficacy of a simplified modified Atkins diet in children with refractory epilepsy (Phase 2/3).
-
CLINICAL_TRIALS trial_result · 2019-01-15Clinical Trial Update: Evaluation of the Modified Atkins Diet in Young Children With Refractory Epilepsy [Phase 2, Phase 3]
A clinical trial evaluating the modified Atkins diet for young children with refractory epilepsy has completed Phase 2 and Phase 3.
-
CLINICAL_TRIALS trial_result · 2019-01-14Clinical Trial Update: A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters [Phase 3]
A Phase 3 long-term safety and tolerability trial of USL261 (brivaracetam) in patients with seizure clusters has been terminated; results we…
-
FDA approval · 2019-01-14FDA Approved: VIGABATRIN — Original Application (Actavis Pharma, Inc.)
FDA page documents Actavis Pharma's original application for a generic Vigabatrin product, seeking approval to market a generic version.
-
FDA approval · 2019-01-09FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
The FDA granted approval of a supplemental application for VIMPAT (lacosamide) submitted by UCB, Inc., to update or expand its labeling.
-
FDA approval · 2019-01-09FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for Vimpat (lacosamide) submitted by UCB, Inc.
-
FDA approval · 2019-01-09FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) submitted by UCB, Inc. The approval represents a modification to the product…
-
CLINICAL_TRIALS trial_result · 2019-01-09Clinical Trial Update: Effects of Transcranial Direct Current Stimulation (TDCS) in Drug-resistant Partial Epilepsy [Phase 2]
Phase 2 trial update evaluating transcranial direct current stimulation in drug-resistant partial epilepsy has completed.
-
FDA approval · 2019-01-04FDA Approved: TRILEPTAL — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for TRILEPTAL (oxcarbazepine) submitted by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2019-01-04FDA Approved: TRILEPTAL — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Trileptal (oxcarbazepine) submitted by Novartis Pharmaceuticals Corporation.
-
FDA label_change · 2018-12-27FDA Approved: TOPAMAX — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved a supplemental application for TOPAMAX (topiramate) by Janssen Pharmaceuticals, Inc., resulting in labeling changes for the dru…
-
FDA approval · 2018-12-27FDA Approved: TOPAMAX — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for TOPAMAX (topiramate) from Janssen Pharmaceuticals, Inc.
-
FDA approval · 2018-12-20FDA Approved: ELEPSIA XR 1000 MG — Original Application (TRIPOINT THERAPEUTICS, LLC)
The FDA approved Elepsia XR 1000 mg, an extended-release formulation of levetiracetam, under an original NDA from TriPoint Therapeutics.
-
CLINICAL_TRIALS trial_result · 2018-12-19Clinical Trial Update: Safety and Pharmacokinetics Study of E2007 to Treat Partial and Generalised Seizures in People With Epilepsy [Phase 2]
Phase 2 safety and pharmacokinetics study of E2007 for partial and generalized seizures in epilepsy completed.
-
FDA approval · 2018-12-13FDA Approved: OXTELLAR XR — Supplemental Application (Supernus Pharmaceuticals, Inc.)
FDA approved a supplemental NDA for OXTELLAR XR (oxcarbazepine) from Supernus Pharmaceuticals, Inc. The supplemental approval encompasses an…
-
CLINICAL_TRIALS trial_result · 2018-12-07Clinical Trial Update: PRX-00023 Therapy in Localization-Related Epilepsy [Phase 2]
Phase 2 trial update for PRX-00023 in localization-related epilepsy (temporal lobe). Trial status terminated; results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-12-05Clinical Trial Update: This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment [Phase 3]
A Phase 3 trial evaluating long-term safety and tolerability of brivaracetam in epilepsy has completed with open-label extension data availa…
-
FDA approval · 2018-12-03FDA Approved: DILANTIN — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for Dilantin (extended phenytoin sodium) filed by Viatris Specialty LLC.
-
FDA approval · 2018-12-03FDA Approved: PHENYTOIN INFATABS — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application for Phenytoin Infatabs, a generic phenytoin product manufactured by Prasco Laboratories.